Researchers at the University of Tennessee College of Medicine at Chattanooga and Erlanger Health studied Ornim Medical’s c-FLOW monitor. They found the monitor could identify the exact time when cerebral blood flow was reestablished and hemispheric asymmetries of flow normalized. This lets clinicians determines if the approach in care or therapy was immediately effective after events like acute ischemic strokes or brain injuries.

Thomas Devlin, M.D., Ph.D., director of the Chattanooga Center for Neurologic Research and Chief of the Division of Neurology at the University of Tennessee College of Medicine Chattanooga, was the study’s lead. Surgical Products was able to connect with him to discuss the study and c-FLOW.

What are the primary benefits to the noninvasive approach offered by c-FLOW?

One of the most important challenges we face, as neurocritical care and stroke doctors, is to develop a way to directly and continuously measure cerebral blood flow in patients.

Currently, we have no ideal technology. We are relegated to use other measures and variables that allow us to estimate cerebral blood flow, albeit fairly inaccurately. While we are able to measure mean arterial pressure and intracranial pressure, important variables affecting cerebral blood flow, technology has not been at hand that allows us monitor and maximize cerebral blood flow continuously at the bedside. The ability to monitor and thereby maximize cerebral blood flow in real-time in patients with critical brain injuries represents one of the major technological challenges in modern medicine. Such technology would drive to improved outcomes in numerous types of injury such as neuro-trauma, stroke and increased intracranial pressure to name just a few.

The c-FLOW cerebral perfusion monitor offers this potential – the importance of this technology cannot be overstated. In carrying out my studies of the use of the c-FLOW monitor, I have found that this technology is reliable, easy to use, and potentially revolutionary in its ability to provide real-time, continuous cerebral flow monitoring in the care of neuro-critical care patients.

How does this technology differ from approaches currently in use?

While other technologies exist that measure cerebral blood flow, the noninvasive and continuous monitoring platform that c-FLOW offers combined with its accuracy and reliability make it a totally unique technology.

What have been the primary obstacles to introducing this product?

While we have been very impressed with the overall performance of c-FLOW under a number of monitoring conditions, ongoing studies designed to fully validate the technology are still ongoing.

How can it be integrated into the approach for patients requiring this type of care?

With the c-FLOW monitor’s ease of use providing tremendously valuable physiological data to the physician, the technology should become a go-to device in emergency rooms, critical care intensive care units, operating rooms, and angiogram suites around the world.

Any additional thoughts?

Having worked closely with Ornim and the c-FLOW’s technology for the past two years, I am tremendously excited about what I firmly believe is a “game-changing” technology in the care of patients with brain at risk.